SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-351083"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-351083" > Influence of Age on...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00009490naa a2200889 4500
001oai:DiVA.org:uu-351083
003SwePub
008180518s2018 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:137861689
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3510832 URI
0247 a https://doi.org/10.1016/j.bbmt.2017.11.0042 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1378616892 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Qayed, Munau Emory Univ, Sch Med, Aflac Canc & Blood Disorders Ctr, 2015 Uppergate Dr NE, Atlanta, GA, USA4 aut
2451 0a Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia :b Implications for Prophylaxis
264 1b Elsevier BV,c 2018
338 a print2 rdacarrier
520 a Relapse remains the major cause of mortality after hematopoietic cell transplantation (HCT) for pediatric acute leukemia. Previous research has suggested that reducing the intensity of calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis may be an effective strategy for abrogating the risk of relapse in pediatric patients undergoing matched sibling donor (MSD) HCT. We reasoned that the benefits of this strategy could be maximized by selectively applying it to those patients least likely to develop GVHD. We conducted a study of risk factors for GVHD, to risk-stratify patients based on age. Patients age <18 years with leukemia who received myeloablative, T cell-replete MSD bone marrow transplantation and calcineurin inhibitor-based GVHD prophylaxis between 2000 and 2013 and were entered into the Center for International Blood and Marrow Transplant Research registry were included. The cumulative incidence of grade II-IV acute GVHD (aGVHD) was 19%, that of grade II-IV aGVHD 7%, and that of chronic GVHD (cGVHD) was 16%. Compared with age 13 to 18 years, age 2 to 12 years was associated with a lower risk of grade II-IV aGVHD (hazard ratio [HR], .42; 95% confidence interval [CI], .26 to .70; P = .0008), grade II-IV aGVHD (HR, .24; 95% CI, .10 to .56; P = .001), and cGVHD (HR, .32; 95% CI, .19 to .54; P < .001). Compared with 2000-2004, the risk of grade II-IV aGVHD was lower in children undergoing transplantation in 2005-2008 (HR, .36; 95% CI, .20 to .65; P = .0007) and in 2009-2013 (HR, .24; 95% CI. .11 to .53; P = .0004). Similarly, the risk of grade III-IV aGVHD was lower in children undergoing transplantation in 2005-2008 (HR, .23; 95% CI, .08 to .65; P = .0056) and 2009-2013 (HR, .16; 95% CI, .04 to .67; P = .0126) compared with those doing so in 2000-2004. We conclude that aGVHD rates have decreased significantly over time, and that children age 2 to 12 years are at very low risk for aGVHD and cGVHD. These results should be validated in an independent analysis, because these patients with high-risk malignancies may be good candidates for trials of reduced GVHD prophylaxis.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng
653 a GVHD
653 a Matched sibling donor transplantation
653 a Children
653 a Recipient age
653 a Leukemia
7001 a Wang, Taou Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI, USA; Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI , USA4 aut
7001 a Hemmer, Michael T.u Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI, USA4 aut
7001 a Spellman, Stephenu Natl Marrow Donor Program Be Match, Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN, USA4 aut
7001 a Arora, Muktau Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN, USA4 aut
7001 a Couriel, Danielu Utah Blood & Marrow Transplant Program, Div Hematol & Hematol Malignancies, Dept Internal Med, Salt Lake City, UT USA4 aut
7001 a Alousi, Aminu Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Stem Cell Transplantat, Houston, TX, USA4 aut
7001 a Pidala, Josephu H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA4 aut
7001 a Abdel-Azim, Hishamu Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA, USA4 aut
7001 a Aljurf, Mahmoudu King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh, Saudi Arabia4 aut
7001 a Ayas, Mouhabu King Faisal Specialist Hosp & Res Ctr, Dept Pediat Hematol Oncol, Riyadh, Saudi Arabia4 aut
7001 a Bitan, Menachemu Tel Aviv Sourasky Med Ctr, Dept Pediat Hematol Oncol, Tel Aviv, Israel4 aut
7001 a Cairo, Mitchellu New York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY, USA4 aut
7001 a Choi, Sung Wonu Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI, USA4 aut
7001 a Dandoy, Christopheru Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH, USA4 aut
7001 a Delgado, Davidu Indiana Univ Hosp, Dept Pediat, Indianapolis, IN, USA4 aut
7001 a Gale, Robert Peteru Imperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England4 aut
7001 a Hale, Gregoryu Johns Hopkins All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL, USA4 aut
7001 a Frangoul, Haydaru TriStar Centennial, Childrens Hosp, Pediat Hematol Oncol, Nashville, TN USA; Sarah Cannon Res Inst, Nashville, TN, USA4 aut
7001 a Kamble, Rammurti T.u Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX, USA4 aut
7001 a Kharfan-Dabaja, Mohamedu H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA4 aut
7001 a Lehman, Leslieu Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA, USA4 aut
7001 a Levine, Johnu Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY, USA4 aut
7001 a MacMillan, Margaretu Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN, USA4 aut
7001 a Marks, David I.u Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England4 aut
7001 a Nishihori, Taigau H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA4 aut
7001 a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden4 aut0 (Swepub:uu)riols677
7001 a Hematti, Peimanu Univ Wisconsin Hosp & Clin, Dept Med, Div Hematol Oncol Bone Marrow Transplantat, Madison, WI, USA4 aut
7001 a Ringden, Olovu Karolinska Institutet4 aut
7001 a Saad, Aymanu Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL, USA4 aut
7001 a Satwani, Prakashu Columbia Univ, Med Ctr, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, New York, NY, USA4 aut
7001 a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN, USA4 aut
7001 a Schultz, Kirk R.u Univ British Columbia, British Columbias Childrens Hosp, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Vancouver, BC, Canada4 aut
7001 a Seo, Sachikou East Hosp, Natl Canc Res Ctr, Kashiwa, Chiba, Japan4 aut
7001 a Shenoy, Shaliniu Washington Univ, Dept Pediat Hematol Oncol, St Louis, MO, USA4 aut
7001 a Waller, Edmund K.u Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA, USA4 aut
7001 a Yu, Lolieu Louisiana State Univ, Hlth Sci Ctr, Ctr Canc & Blood Disorders, Div Hematol Oncol, New Orleans, LA, USA4 aut
7001 a Horowitz, Mary M.u Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI, USA4 aut
7001 a Horan, Johnu Emory Univ, Sch Med, Aflac Canc & Blood Disorders Ctr, Atlanta, GA, USA4 aut
7102 a Emory Univ, Sch Med, Aflac Canc & Blood Disorders Ctr, 2015 Uppergate Dr NE, Atlanta, GA, USAb Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI, USA; Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI , USA4 org
7730 t Biology of blood and marrow transplantationd : Elsevier BVg 24:3, s. 521-528q 24:3<521-528x 1083-8791x 1523-6536
8564 u http://www.bbmt.org/article/S1083879117308182/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-351083
8564 8u https://doi.org/10.1016/j.bbmt.2017.11.004
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:137861689

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy